GlassScriptPhysician profile
Brenna L Fitzgerald
NPI 1437337110
$46,137.10
in general payments reported to CMS, 2019-2025
42 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $13K · 2023: $2,589 · 2024: $2,890 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,103 · Consulting Fee: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,102.76 |
| Consulting Fee | $1,660.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,910.66 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $9,278.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,726.07 | 2022 | |
| Emd Serono, INC. | $3,913.81 | 2021-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $3,465.70 | 2021-2025 | Ultomiris, Soliris |
| Janssen Biotech, INC. | $1,410.66 | 2025 | |
| Biogen, INC. | $1,393.40 | 2021-2025 | Vumerity, Tysabri |
| Allergan, INC. | $1,250.00 | 2021 | |
| Pfizer INC. | $855.12 | 2023-2025 | |
| Amgen INC. | $843.77 | 2021-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $724.62 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $487.28 | 2021-2025 | |
| Lundbeck LLC | $463.53 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $437.18 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $412.73 | 2021-2025 | Zeposia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $403.56 | 2021-2025 | Crexont, Rytary, Lyvispah |
| Ucb, INC. | $367.64 | 2021-2025 | Zilbrysq |
| Kyowa Kirin, INC. | $319.00 | 2021-2024 | Nourianz |
| Mdd US Operations, LLC | $307.68 | 2022-2025 | Apokyn, Gocovri, Xadago |
| Horizon Therapeutics Plc | $240.13 | 2021-2023 | Uplizna |
| Neurocrine Biosciences, INC. | $206.26 | 2021-2025 | Ingrezza, Ongentys |
| Eisai INC. | $193.49 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $153.37 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $143.86 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Upsher-Smith Laboratories LLC | $139.50 | 2021-2023 | |
| Argenx US, INC. | $138.06 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $136.95 | 2022-2025 | Nuplazid |
| Sk Life Science, INC. | $118.56 | 2022-2025 | |
| Banner Life Sciences, LLC | $117.27 | 2022-2023 | |
| Genentech USA, INC. | $108.96 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $85.22 | 2024 | |
| Genzyme Corporation | $80.21 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $53.48 | 2024-2025 | Purified Cortrophin Gel |
| Avion Pharmaceuticals | $53.17 | 2022 | |
| Scilex Pharmaceuticals INC. | $40.53 | 2025 | |
| Mallinckrodt Hospital Products INC. | $35.41 | 2025 | Acthar |
| Impel Pharmaceuticals INC. | $30.05 | 2022-2023 | Trudhesa |
| Livanova USA, INC. | $23.56 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Arbor Pharmaceuticals, INC. | $18.57 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.08 | 2022 | |
| Corium, LLC | $16.49 | 2023 | Adlarity |
| Neurelis, INC. | $15.97 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenna Fitzgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.